OPtimisation of Surgical Repair for Treating Insufficiency of the MItral Valve - Safety and Effectiveness Evaluation

Not Applicable

Recruiting

• Conditions: Mitral Valve Regurgitation
• Interventions: Device: Kalios Implant

• Registration Number: NCT03908983
• Lead Sponsor: Kephalios

Brief Summary

KALIOS is indicated for the surgical treatment of mitral regurgitation by mitral valve repair.It is intended for mitral valve repair using conventional open heart or minimally invasive techniques.

The KALIOS device is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3

The primary objective of this clinical investigation is to assess the safety and effectiveness of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s) The secondary objectives are to investigate the effects of KALIOS for the surgical treatment of Mitral Regurgitation on cardiac function and on patient functional status This clinical trial is prospective, non-randomized, single arm, multicentric \& international. Up to 100 patients are expected to be enrolled to obtain 62 evaluable patients at one year,presenting with primary (degenerative) or secondary (functional) mitral valve regurgitation and who are candidate to a mitral valve repair.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-04-05
• Study First Submitted QC: 2019-04-08
• Study First Posted: 2019-04-09
• Study Start: 2019-11-20
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-25
• Last Update Posted: 2021-02-26
• Primary Completion: 2021-05-31
• Study Completion: 2025-05-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patients must meet ALL the following inclusion criteria :

1. with primary or secondary mitral regurgitation recorded by TTE and confirmed during TEE where surgery for mitral valve repair is required with indications consistent with AHA/ACC and ESC/EACTS guidelines :

   1. primary (degenerative) : severe MR grade parameters (R Vol and EROA measured by PISA methods):

      • EROA regurgitant >60 ml and
      • Vena contracta width > 7mm and
      • Regurgitant fraction >50%

   2. Secondary (functional) : severe MR (EROA ≥30 mm²; R Vol > 30ml) may differ from the primary MR and are based on the prognostic value of these thresholds to predict the poor outcome, or for patients undergoing CABG

2. with LVEF ≥ 30%

3. in satisfactory condition, based on the physical examination and investigator's experience, with a life expectancy above one year after the intervention

4. with or without concomitant procedures as: CABG, other valve repair/replacement, pacemaker implantation, exclusion of left appendage (with device or surgically) and Maze (or PVI) procedure

5. willing to sign the informed consent;

6. able and willing to comply with all clinical investigation requirements, including the required study follow-up visits

Exclusion Criteria

• Patients will be excluded if ANY of the following conditions are present:

  1. of age < 21 years;

  2. with echocardiographic measurements predicting SAM

     1. LVEDD < 45 mm
     2. C-Sd < 25mm (distance from the septum to the mitral valve coaptation point)
     3. Basal-IVDd > 15 mm
     4. aorto-mitral angle < 120°
     5. pre-repair posterior leaflet height > 15 mm

  3. with cardiogenic shock;

  4. with active endocarditis (or having had active endocarditis in the last three months);

  5. with active myocarditis;

  6. with heavily calcified mitral annulus;

  7. with mitral stenosis;

  8. unable to take anticoagulation medications;

  9. with a known untreatable allergy to contrast media or nickel;

  10. with a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy shorter than 1 year, or for whom the implant of the device produces an unacceptable increase of risk;

  11. with contraindication to transoesophageal echocardiography;

  12. with contraindication to cardiopulmonary bypass;

  13. who are pregnant or breast-feeding women;

  14. involved in any other clinical investigation for drugs or devices;

  15. unable to understand and sign the ICF in absence of legal protection;

  16. unable to read and write;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Implanted Patients	Kalios Implant	Implantation of Kalios Device

Primary Outcome Measures

Name	Time	Method
Assessment of the effectiveness of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s)	At 1 year	Absence of Mitral Regurgitation of grade \> 2 (through echographic assessment)
Assessment of the safety of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s)Regurgitation with optional intra-operative and/or post-operative adjustment(s)	At 1 year	Incidence of Major Adverse Cardiac Events (MACE)

Secondary Outcome Measures

Name	Time	Method
Assessment of the effectiveness of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s) at each follow up	at 1, 3 6, 24, 36, 48 and 60 months	Absence of Mitral Regurgitation of grade \> 2 (through echographic assessment)
Assessment of the adjustment functionality of the device	after any optional adjustment(s) performed immediately after annuloplasty, or following follow up visits at 1, 3, 6, 12, 24, 36, 48 and 60 months	Assessment of the increase of mitral leaflets coaptation length (through echographic assessment)
Assessment of the safety of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s)at each follow up	at 1, 3, 6, 24, 36, 48 and 60 months	Incidence of Major Adverse Cardiac Events (MACE)

Trial Locations

Locations (9)

Centre Hospitalier Universitaire Vaudois; 🇨🇭 Lausanne, Switzerland

University Clinic of Cardiac Surgery, Heart Center; 🇩🇪 Leipzig, Germany

Klinikum Passau; 🇩🇪 Passau, Germany

Careggi Hospital; 🇮🇹 Florence, Italy

Humanitas Research Hospital; 🇮🇹 Milan, Italy

Maria Cecilia Hospital Cotignola; 🇮🇹 Cotignola, Italy

Medical University of Vienna - Department of Surgery, Division of Cardiac Surgery; 🇦🇹 Vienna, Austria

Maria Eleonora Hospital Palermo; 🇮🇹 Palermo, Italy

Ospedale Luigi Sacco; 🇮🇹 Milan, Italy